Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. more
Time Frame | AVIR | Sector | S&P500 |
---|---|---|---|
1-Week Return | 9.49% | 2.3% | 1.73% |
1-Month Return | 1.17% | -1.77% | 3.44% |
3-Month Return | -9.9% | -6.07% | 7.02% |
6-Month Return | -4.16% | 2.45% | 13.38% |
1-Year Return | 20.14% | 12.17% | 32.25% |
3-Year Return | -55.87% | 10.46% | 29.27% |
5-Year Return | -88.6% | 46.4% | 90.61% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 48.63M | 351.37M | 192.18M | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":13.84,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":54.69,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 17.00K | 19.00K | 29.00K | 260.00K | 70.09M | [{"date":"2019-12-31","value":0.02,"profit":true},{"date":"2020-12-31","value":0.03,"profit":true},{"date":"2021-12-31","value":0.04,"profit":true},{"date":"2022-12-31","value":0.37,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (17.00K) | 48.61M | 351.37M | (260.00K) | (70.09M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":13.84,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-0.07,"profit":false},{"date":"2023-12-31","value":-19.95,"profit":false}] |
Gross Margin | - | 99.96% | 100.00% | (0.14%) | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":99.96,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-0.14,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 14.61M | 59.66M | 212.99M | 130.65M | 94.07M | [{"date":"2019-12-31","value":6.86,"profit":true},{"date":"2020-12-31","value":28.01,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":61.34,"profit":true},{"date":"2023-12-31","value":44.17,"profit":true}] |
Operating Income | (14.61M) | (11.03M) | 138.38M | (130.65M) | (164.16M) | [{"date":"2019-12-31","value":-10.56,"profit":false},{"date":"2020-12-31","value":-7.97,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-94.42,"profit":false},{"date":"2023-12-31","value":-118.63,"profit":false}] |
Total Non-Operating Income/Expense | 1.15M | 166.00K | 426.00K | 22.30M | 58.45M | [{"date":"2019-12-31","value":1.96,"profit":true},{"date":"2020-12-31","value":0.28,"profit":true},{"date":"2021-12-31","value":0.73,"profit":true},{"date":"2022-12-31","value":38.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (14.03M) | (10.95M) | 138.59M | (119.50M) | (134.94M) | [{"date":"2019-12-31","value":-10.13,"profit":false},{"date":"2020-12-31","value":-7.9,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-86.22,"profit":false},{"date":"2023-12-31","value":-97.36,"profit":false}] |
Income Taxes | (574.00K) | (83.00K) | 17.40M | (3.59M) | 1.02M | [{"date":"2019-12-31","value":-3.3,"profit":false},{"date":"2020-12-31","value":-0.48,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-20.63,"profit":false},{"date":"2023-12-31","value":5.85,"profit":true}] |
Income After Taxes | (13.46M) | (10.86M) | 121.19M | (115.91M) | (135.96M) | [{"date":"2019-12-31","value":-11.11,"profit":false},{"date":"2020-12-31","value":-8.96,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-95.64,"profit":false},{"date":"2023-12-31","value":-112.18,"profit":false}] |
Income From Continuous Operations | (14.03M) | (10.95M) | 121.19M | (115.91M) | (135.96M) | [{"date":"2019-12-31","value":-11.58,"profit":false},{"date":"2020-12-31","value":-9.03,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-95.64,"profit":false},{"date":"2023-12-31","value":-112.18,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (13.46M) | (10.86M) | 121.19M | (115.91M) | (135.96M) | [{"date":"2019-12-31","value":-11.11,"profit":false},{"date":"2020-12-31","value":-8.96,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-95.64,"profit":false},{"date":"2023-12-31","value":-112.18,"profit":false}] |
EPS (Diluted) | - | (0.97) | 1.36 | (1.40) | (1.64) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-71.32,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-102.94,"profit":false},{"date":"2023-12-31","value":-120.59,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
AVIR | |
---|---|
Cash Ratio | 19.17 |
Current Ratio | 19.33 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
AVIR | |
---|---|
ROA (LTM) | -14.25% |
ROE (LTM) | -33.46% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
AVIR | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.07 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.93 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
AVIR | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 1.90 |
P/B | 0.61 |
Price/FCF | NM |
EV/R | 58.97 |
EV/Ebitda | NM |
Atea Pharmaceuticals Inc (AVIR) share price today is $3.46
Yes, Indians can buy shares of Atea Pharmaceuticals Inc (AVIR) on Vested. To buy Atea Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AVIR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Atea Pharmaceuticals Inc (AVIR) via the Vested app. You can start investing in Atea Pharmaceuticals Inc (AVIR) with a minimum investment of $1.
You can invest in shares of Atea Pharmaceuticals Inc (AVIR) via Vested in three simple steps:
The 52-week high price of Atea Pharmaceuticals Inc (AVIR) is $4.6. The 52-week low price of Atea Pharmaceuticals Inc (AVIR) is $2.88.
The price-to-earnings (P/E) ratio of Atea Pharmaceuticals Inc (AVIR) is
The price-to-book (P/B) ratio of Atea Pharmaceuticals Inc (AVIR) is 0.61
The dividend yield of Atea Pharmaceuticals Inc (AVIR) is 0.00%
The market capitalization of Atea Pharmaceuticals Inc (AVIR) is $278.73M
The stock symbol (or ticker) of Atea Pharmaceuticals Inc is AVIR